July 2013, Array BioPharma (ARRY) entered into a Drug Discovery Collaboration Agreement with Loxo Oncology (LOXO) @LoxoOncology, and granted Loxo exclusive rights to develop and commercialize certain Array invented compounds targeted at the tropomyosin kinase (“Trk”) family of receptors, including LOXO-101. In April 2014 and again in April 2015, Array and Loxo amended the agreement […]